Log In
Print
BCIQ
Print
Print this Print this
 

PF-582

  Manage Alerts
Collapse Summary General Information
Company Pfenex Inc.
DescriptionBiosimilar of ranibizumab
Molecular Target
Mechanism of ActionAntibody; Biosimilar
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I/II
Standard IndicationAge-related macular degeneration (AMD)
Indication DetailsTreat wet age-related macular degeneration (AMD)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today